Please Wait.....
Report
Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Market Research Report I 2025-03-25 I 160 Pages I BCC Research
Description
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Executive Summary
Summary:
The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
CAR T-cell therapy is a novel method for treating hematologic tumors that were previously considered incurable and have been developed by modifying a patient's T cells to express a chimeric antigen receptor (CAR) unique to a tumor antigen (TA). The foundation of this treatment is the CAR's ability to attach to antigens, which results in a strong T-cell activation and anti-tumor response. Tisagenlecleucel was the first FDA-licensed CAR T-cell therapy authorized in 2017 for treating acute lymphoblastic leukemia in children and young adults.
CAR T-cell therapy holds a huge potential benefit, due to its being tailored to each patient's needs. To target and eliminate cancer cells, T cells are extracted from the patient, genetically altered in the lab to produce CARs on their surface and reintroduced into the patient. CAR T-cell-based treatments have attracted much interest in solid tumors because of their remarkable effectiveness in hematological malignancies. There are now six autologous CAR T-cell treatments that have received FDA approval and are used to treat different types of blood cancer in the U.S. CAR T-cell treatments are being studied in 1,439 clinical studies worldwide in addition to these commercially available products.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy
Chapter 4 Emerging Technologies and Clinical Trials
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China
Chapter 5 Market Segmentation Analysis
Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Patent Review and New Developments
Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG
Chapter 7 Competitive Intelligence
Ranking of Leading Players
Strategic Considerations
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.
List of Tables
Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017-2022
Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 4 : Global Cancer Statistics, 2022
Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
Table 17 : Bluebird Bio: Patents and Patent Applications, 2012-2021
Table 18 : Celgene Corp.: Patents and Patent Applications, 2018-2021
Table 19 : Cellectis: Patents and Patent Applications, 2018-2021
Table 20 : Editas Medicine: Patent Applications, 2015-2021
Table 21 : Eureka Therapeutics: Patent Applications, 2012-2021
Table 22 : iCell Gene Therapeutics: Patent Applications, 2017-2019
Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000-2021
Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013-2021
Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
Table 27 : Focus Areas in ESG Metrics
Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
Table 29 : Abbreviations Used in this Report
Table 30 : AbbVie Inc.: Company Snapshot
Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 32 : AbbVie Inc.: Product Portfolio
Table 33 : AbbVie Inc.: News/Key Developments, 2023-2024
Table 34 : Allogene Therapeutics: Company Snapshot
Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 36 : Allogene Therapeutics: Product Portfolio
Table 37 : Allogene Therapeutics: News/Key Developments, 2024
Table 38 : Amgen Inc.: Company Snapshot
Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Amgen Inc.: Product Portfolio
Table 41 : Amgen Inc.: News/Key Developments, 2024
Table 42 : AstraZeneca: Company Snapshot
Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 44 : AstraZeneca: Product Portfolio
Table 45 : AstraZeneca: News/Key Developments, 2023-2024
Table 46 : Bluebird Bio Inc.: Company Snapshot
Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
Table 48 : Bluebird Bio Inc.: Product Portfolio
Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2024
Table 54 : Cellectis S.A.: Company Snapshot
Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
Table 56 : Cellectis S.A.: Product Portfolio
Table 57 : Cellectis S.A.: News/Key Developments, 2023-2024
Table 58 : Eureka Therapeutics Inc.: Company Snapshot
Table 59 : Eureka Therapeutics Inc: Product Portfolio
Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023-2024
Table 61 : Gilead Sciences Inc.: Company Snapshot
Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Gilead Sciences Inc.: Product Portfolio
Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022-2024
Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 72 : Les Laboratoires Servier: Company Snapshot
Table 73 : Les Laboratoires Servier: Product Portfolio
Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
Table 75 : Novartis AG: Company Snapshot
Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 77 : Novartis AG: Product Portfolio
Table 78 : Novartis AG: News/Key Developments, 2021-2024
Table 79 : Pfizer Inc.: Company Snapshot
Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Pfizer Inc.: Product Portfolio
Table 82 : Pfizer Inc.: News/Key Developments, 2023
Table 83 : Protheragen Inc.: Company Snapshot
Table 84 : Protheragen Inc.: Product Portfolio
List of Figures
Summary Figure : Global Market for CAR T-Cell Therapy, by Product, 2022-2029
Figure 1 : Historical Development of CAR T-Cell Therapy, 1992-2017
Figure 2 : Snapshot of the Market Dynamics for CAR T-Cell Therapy
Figure 3 : Estimated New Cancer Cases, 2022, 2045 and 2050
Figure 4 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Status, January 2023
Figure 5 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Study Phase, January 2023
Figure 6 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Investigator Type, January 2023
Figure 7 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2021-2024
Figure 8 : Global Market Shares of CAR T-Cell Therapy, by Product, 2024
Figure 9 : Global Market Shares for Yescarta, by Region, 2024
Figure 10 : Global Market Shares for Kymriah, by Region, 2024
Figure 11 : Global Market Shares for Tecartus, by Region, 2024
Figure 12 : Global Market Shares for Abecma, by Region, 2024
Figure 13 : Global Market Shares for Breyanzi, by Region, 2024
Figure 14 : Global Market Shares for Carvykti, by Region, 2024
Figure 15 : Global Market Shares of CAR T-Cells Therapy, by Indication, 2024
Figure 16 : Global Market Shares of CAR T-Cell Therapy, by Region, 2024
Figure 17 : Strategic Considerations
Figure 18 : How a Strong ESG Proposition Benefits Businesses
Figure 19 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 20 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 21 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 23 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 24 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 25 : Bristol Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 26 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 27 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 28 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 29 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 30 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security